This Article Full Text Full Text (PDF) Online Supplement All Versions of this Article: 200503-379OCv1 172/4/494    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Spuentrup, E. Articles by Buecker, A. Search for Related Content PubMed PubMed Citation Articles by Spuentrup, E. Articles by Buecker, A.

Molecular Magnetic Resonance Imaging of Pulmonary Emboli with a Fibrin-specific Contrast Agent

Department of Diagnostic Radiology, Aachen Technical University, Aachen, Germany; Epix Pharmaceuticals, Cambridge; and Department of Medicine (Cardiovascular Division), Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts

Correspondence and requests for reprints should be addressed to Elmar Spuentrup, M.D., Department of Diagnostic Radiology, University Hospital, Aachen Technical University, Pauwelsstrasse 30, 52057 Aachen, Germany. E-mail: spuenti{at}rad.rwth-aachen.de

Rationale and Objectives: The detection of pulmonary embolism is still challenging due to the often nonspecific clinical findings. The aim of this study was to investigate the potential of molecular targeted magnetic resonance imaging (MRI) of pulmonary emboli using low-dose application of a fibrin-specific contrast agent (EP-2104R; Epix Pharmaceuticals, Cambridge, MA). Methods: Fresh clots from human blood were engineered ex vivo and delivered in the lungs of 11 swine. Subsequently, a T1-weighted breath-hold three-dimensional gradient-echo sequence was performed before as well as 5 minutes, 1 hour, and 2 hours after systemic administration of 7.5 (n = 5) or 4 (n = 5) µmol/kg EP-2104R. One swine that did not receive any contrast agent served as a control. MR images were analyzed by two investigators and contrast-to-noise ratio between the thrombus and the surrounding tissue (blood pool and lung parenchyma) was assessed. Localization of thrombi was compared with 16-row multislice computed tomography. Finally, the animals were killed and thrombi were removed for assessment of gadolinium concentration. Main Results: Before contrast media application, thrombi were not visible on MR images. At 1 and 2 hours after contrast media injection, pulmonary emboli were selectively visualized with high-signal intensity foci, independent of the dosage used. A high gadolinium concentration in thrombi was found after both dosages (83 ± 41 µM for 4 µmol/kg and 130 ± 57µM for 7.5 µmol/kg), resulting in a similar high contrast-to-noise ratio on MR images (between 11 and 13). Conclusion: Systemic low-dose application of EP-2104R allows for selective molecular MRI of fresh pulmonary thromboembolism in a swine model.

Key Words: contrast • embolism • fibrin • magnetic resonance imaging • molecular imaging • pulmonary vessel

This article has been cited by other articles:

				F. A. Jaffer, P. Libby, and R. Weissleder Molecular Imaging of Cardiovascular Disease Circulation, August 28, 2007; 116(9): 1052 - 1061. [Full Text] [PDF]

				C. P. Stracke, M. Katoh, A. J. Wiethoff, E. C. Parsons, P. Spangenberg, and E. Spuntrup Molecular MRI of Cerebral Venous Sinus Thrombosis Using a New Fibrin-Specific MR Contrast Agent Stroke, May 1, 2007; 38(5): 1476 - 1481. [Abstract] [Full Text] [PDF]

				M. M. Hoeper and L. J. Rubin Update in pulmonary hypertension 2005. Am. J. Respir. Crit. Care Med., March 1, 2006; 173(5): 499 - 505. [Full Text] [PDF]